Comparative Pharmacology
Head-to-head clinical analysis: ASPRUZYO SPRINKLE versus LANSOPRAZOLE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ASPRUZYO SPRINKLE versus LANSOPRAZOLE.
ASPRUZYO SPRINKLE vs LANSOPRAZOLE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
ASPRUZYO SPRINKLE (lacosamide) enhances slow inactivation of voltage-gated sodium channels, stabilizing neuronal membranes and inhibiting repetitive neuronal firing.
Proton pump inhibitor that inhibits gastric acid secretion by binding to the H+/K+ ATPase enzyme (proton pump) in gastric parietal cells, preventing the final step of acid production.
Oral: 30 mg once daily, with or without food. Sprinkle capsules can be opened and contents mixed with soft food or liquid.
15-30 mg orally once daily; 30 mg IV over 30 minutes once daily (when oral not possible).
None Documented
None Documented
Terminal half-life is approximately 20-30 hours, allowing for once-daily dosing. Steady-state achieved within 5-7 days.
Clinical Note
moderateDexlansoprazole + Clodronic acid
"The therapeutic efficacy of Clodronic acid can be decreased when used in combination with Dexlansoprazole."
Clinical Note
moderateLansoprazole + Clodronic acid
"The therapeutic efficacy of Clodronic acid can be decreased when used in combination with Lansoprazole."
Clinical Note
moderateDexlansoprazole + Alendronic acid
"The therapeutic efficacy of Alendronic acid can be decreased when used in combination with Dexlansoprazole."
Clinical Note
moderateTerminal elimination half-life: 1.5-2 hours (increased to 3-6 hours in elderly, hepatic impairment).
Primarily hepatic metabolism via CYP3A4 and CYP2C9, with <2% excreted unchanged in urine. Biliary/fecal excretion accounts for >90% of metabolites.
Renal (14-23% as metabolites); biliary/fecal (major route, ~60% as metabolites and parent drug).
Category C
Category A/B
Proton Pump Inhibitor
Proton Pump Inhibitor
Lansoprazole + Alendronic acid
"The therapeutic efficacy of Alendronic acid can be decreased when used in combination with Lansoprazole."